Obagi Medical Partners with Alpha Aesthetic for Real-World Evidence Study on saypha MagIQ
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Alpha Aesthetic Partners for the ALOHA Program to evaluate Obagi® saypha® MagIQ™ in real-world settings.
- Alpha will conduct a multi-site evaluation across its network of 31 practices in 12 states, focusing on clinical performance and patient experience.
- Initial findings from the program are scheduled to be presented at the upcoming Alpha Summit and key industry conferences.
- Obagi® saypha® MagIQ™ is Obagi’s first FDA-approved injectable hyaluronic acid filler, developed by Croma-Pharma GmbH.
The big picture
This collaboration underscores the growing emphasis on real-world evidence in the aesthetic medicine sector, as providers seek validated solutions to enhance patient outcomes. Waldencast’s strategic focus on scaling high-growth beauty brands through partnerships aligns with broader industry trends toward data-driven clinical validation and operational excellence.
What we're watching
- Clinical Validation
- How the real-world evidence from the ALOHA Program will impact the adoption of saypha MagIQ™ among aesthetic practices.
- Market Expansion
- Whether Alpha Aesthetic Partners' network can accelerate the rollout of Obagi’s injectable solutions across diverse clinical environments.
- Competitive Positioning
- The pace at which Obagi Medical can differentiate saypha MagIQ™ in a crowded hyaluronic acid filler market.
Our editorial coverage:
Related topics